Online inquiry

IVTScrip™ mRNA-Anti-CD40, CP-870893(Cap 1, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ6196MR)

This product GTTS-WQ6196MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets CD40 gene. The antibody can be applied in Solid tumors, Adenocarcinoma research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001250.6
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 958
UniProt ID P25942
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD40, CP-870893(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ6196MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ12415MR IVTScrip™ mRNA-Anti-CD3E, NI-0401(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA NI-0401
GTTS-WQ7789MR IVTScrip™ mRNA-Anti-env, GS-HIV(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA GS-HIV
GTTS-WQ10312MR IVTScrip™ mRNA-Anti-ERBB3, LJM716(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA LJM716
GTTS-WQ12845MR IVTScrip™ mRNA-Anti-FZD10, ONC-005(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ONC-005
GTTS-WQ15808MR IVTScrip™ mRNA-Anti-CD3E&IL3RA, XmAb14045(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA XmAb14045
GTTS-WQ15290MR IVTScrip™ mRNA-Anti-EGFR, Theraloc(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA Theraloc
GTTS-WQ395MR IVTScrip™ mRNA-Anti-ANGPT2, 2xCon4C(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA 2xCon4C
GTTS-WQ15169MR IVTScrip™ mRNA-Anti-CD6, T1h(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA T1h
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW